2014
DOI: 10.1016/j.jss.2014.07.043
|View full text |Cite
|
Sign up to set email alerts
|

Methylene blue attenuates ischemia–reperfusion injury in lung transplantation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
15
0
2

Year Published

2016
2016
2023
2023

Publication Types

Select...
5
3
2

Relationship

2
8

Authors

Journals

citations
Cited by 24 publications
(18 citation statements)
references
References 28 publications
1
15
0
2
Order By: Relevance
“…Recent studies have identified a variety of strategies including: 1) anti-oxidant strategies using free radical scavengers or inhibitors of oxidant-producing enzymes (e.g. methylene blue [36] or N-acetylcysteine [37]); 2) anti-inflammatory strategies using inhibitors of pro-inflammatory transcription factors (e.g. inhibitor of Egr-1 [27]) or inflammatory mediators (e.g.…”
Section: Strategies To Limit Ir Injurymentioning
confidence: 99%
“…Recent studies have identified a variety of strategies including: 1) anti-oxidant strategies using free radical scavengers or inhibitors of oxidant-producing enzymes (e.g. methylene blue [36] or N-acetylcysteine [37]); 2) anti-inflammatory strategies using inhibitors of pro-inflammatory transcription factors (e.g. inhibitor of Egr-1 [27]) or inflammatory mediators (e.g.…”
Section: Strategies To Limit Ir Injurymentioning
confidence: 99%
“…IL-6 is part of the TNF-α activated pro-inflammatory pathway that has been noted by several groups including our own to be a component of ischemia-reperfusion injury after lung transplant(16, 1822). However, Farivar and colleagues demonstrated reduced endothelial disruption and neutrophil sequestration with recombinant IL-6 in a rat ischemia-reperfusion model of lung transplant highlighting the signal orchestration that can lead to both pro- and anti-inflammatory effects of this cytokine(23).…”
Section: Discussionmentioning
confidence: 70%
“…Lung transplantation has become an effective therapeutic option in the treatment of patients with various end-stage pulmonary diseases [1] such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, bronchiectasis, and primary pulmonary hypertension [2] . Lung injury induced by ischemia-reperfusion (I/R) can lead to severe primary graft failure with about 60% mortality after lung transplantation [3][4][5] .…”
Section: Introductionmentioning
confidence: 99%